Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries

摘要

BackgroundLaboratory testing to identify contraindications and adverse drug reactions is important for safety of patients initiating angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Rates and predictors of appropriate testing among Medicare fee-for-service beneficiaries are unknown.